财务部 | OA    

Brief Introduction to SZPTRI-NJU
栏目:合作项目 发布时间:2019-11-19



Brief Introduction to

Shenzhen Pharmaceutical Technology Research Institute of Nanjing University  

1. Profile  

Shenzhen Pharmaceutical Technology Research Institute is affiliated with Shenzhen Research Institute of Nanjing University and   

co-founded in Shenzhen, among Shenzhen Research Institute of Nanjing University, the State Key Laboratory of Pharmaceutical   

Biotechnology of Nanjing University, HLK Pharmaceuticals Co., Ltd., and HLK Biotechnology Co., Ltd in November of 2013.    

It combines the technical expertise and industrial experience in HLK with the academic strength and research capability of   

NanjingUniversity. With the consolidation of global expertise in pharmaceutical research and development, the goal of the institute   

is to promote technology exchanges between East and West, provide cutting age pharmaceutical development technologies to develop   

and manufacture new pharmaceutical products, as well as advance the development of traditional Chinese medicines according to the   

current development standards and regulations in Chinese and Western markets.  

   

 

On November 15, 2013, a ceremony was held in Shenzhen Virtual University Park at the 2013

Virtual University Park association annual meeting.   

   

 

The Pharmaceutical Technology Research Institute is located in Shenzhen Industry, Education and Research Base of Nanjing University,  

Address: No. 6 Yuexing 3rd road, Southern District of Shenzhen High-tech Industrial Park, Nanshan District, Shenzhen, P.R. China.  

   

 

The laboratory of the Institute is located in the Bio-Incubator of ShenzhenHigh-TechIndustrial Park   

Address: 10 Gaoxin Central. 1ST Ave., Central District of Shenzhen High-tech Industrial Park, Nanshan District, Shenzhen, P.R. China   

 

Management Team of Shenzhen Pharmaceutical Technology Research Institute of NanjingUniversity  

2. Mission  

Our mission is to bridge the technology advances between East and West, provide the best and affordable medicines for patients.  

3. Organization  

The Pharmaceutical Technology Research Institute is organized into six innovation centers:  

(1) Novel Pharmaceutical Products Development Center  

This center is responsible for the development of new chemical entities and new dosage forms of pharmaceutical products, following  

 the international development standards and regulations.  

(2) Generic Pharmaceutical Product Development Center  

This center is responsible for the development of generic pharmaceutical products in the therapeutic areas of cardiovascular, immune   

disease and malignant tumor.  

(3) Nature Pharmaceutical Product Development Center  

This center is responsible for the development of nature pharmaceutical products with the focus of developing TCM (Traditional   

Chinese Medicine) and botanic pharmaceutical products, with the advanced pharmaceutical technologies.  

(4) Pharmaceutical Dosage Form Development Service Center  

The center is responsible for providing services to international clients for the development of varies of pharmaceutical dosage forms.  

(5) International Pharmaceutical Technology Exchange Center  

This center is responsible to be a portal for pharmaceutical technology exchange, and particularly to be a portal for western companies  

 or entrepreneurs to develop pharmaceuticals for the China market.  

(6) Medical Project Investment and Financing Center  

This center is responsible to incubate medical projects and small micro enterprise or create entity companies by working with   

NanjingUniversity, business service companies and VC/PE companies.  

4. Management Team  

(1) The Board of Directors  

The Pharmaceutical Technology Research Institute of Nanjing University  is under the leadership of the board. The board consists  

 of following five members.  

   

Chairman of the Board, Yi PAN  

Professor PAN is a Vice President of Nanjing University  

Board Member, Xuyu  ZHANG  

Professor ZHANG is now a Vice President of Nanjing Normal University.

Prior to this position, he was the Assistant President of Nanjing University

 and the Dean of Shenzhen Research Institute of Nanjing University.  

 

 

 

 

 

 

 

Board Member, Zeren WANG  

Dr. WANG is the co-founder, the Managing Director and CSO of HLK. In this position, he is responsible for the overall science and technical management of the company. He also is the adjunct researcher of the State Key Laboratory of Pharmaceutical Biotechnology of Nanjing University. He has over 15 years of experience in major international pharmaceutical companies (including Novartis and Boehringer Ingelheim) in drug dosage form development. He is specialized in formulation development of poorly water soluble compounds for oral delivery and experienced in the development of oral solid dosage forms (tablets, hard gelatin capsules, soft gelatin capsules), oral liquid dosage forms (solutions and suspensions), controlled release technology, and parenteral (lyophilization). He has 30 peer reviewed publications and patents, as well as numerous poster presentations.

 



Board Member, Zichun HUA  

 

 

Professor HUA is a Vice Dean of College of Life Science, Nanjing University. He is also the director of the State Key Laboratory of Pharmaceutical Biotechnology of Nanjing University, as well as the director of the Shenzhen R&D Section of the State Key Laboratory of Pharmaceutical Biotechnology of Nanjing University. He has been awarded National Outstanding Youth Fund in 2004, and Distinguished Professor for the Cheung Kong scholars program in 2010.

 

Board Member, Jun XU  

Ms. XU is the co-founder and President of HLK. She is responsible for business development, strategy, customer relations, and interacting with governmental agencies and regulators. Jun also works with both Chinese and US-based companies and governments to promote mutual cooperation and business in the biotech and pharmaceutical sectors. Prior to her current position, Jun has over 15 years of experience in major international pharmaceutical companies (including Novartis and Boehringer Ingelheim) in drug discovery and development.

   

(2)The Secretariat  

Secretary-general of the Secretariat, Dong HAN  

Mr. HAN is the dean of the Shenzhen Research Institute of Nanjing University and the chief representative of Nanjing University for the Shenzhen Virtual University Park.

 

(3) The Executive Committee Members  

This executive committee is responsible for the routine activities of the institute. It is also responsible for the decision making and management regarding technology, market, capital operation and the legal activities. The committee is operated under the supervision of the Board of Directors.
The committee is consisting of four following members: Executive Vice Dean, Dr. Zeren WANG; Vice Deans, Dr. Zichun HUA, Mr. Dong HAN and Ms. Jun XU.

(4) Scientific Expert Committee Members

 Dr. Peter FARINA  

Dr. FARINA is an Executive in Residence at Canaan Partners, a venture capital firm, located in Westport, CT where he assesses and advises on pharma/biotech/healthcare investments. He is also the managing partner of a consulting firm, Salient Science & Technology, LLC which advises several biotech firms on strategic and technical matters in pharmaceutical R&D. Dr. Farina currently serves as the Co-Chair and Board Member of Connecticut United for Research Excellence (CURE); the Advisory Board of the University of Connecticut School of Pharmacy, member of the NIH Blueprint Neurotherapeutics Network (BPN) steering committee; Emory University DRIVE Advisory Board, and was a Founder and CEO of Developing World Cures, a nonprofit company working on neglected diseases.

 Professor Dianqing (Dan) WU, PhD  

Dr. WU is the Professor of Pharmacology at the Yale School of Medicine. He also is the adjunct professor of Department of Genetics and Developmental Biology, University of Connecticut. He focuses on studying signal transduction pathways.

Dr. Renxiang TAN   

Dr. TAN is a Professor of Nanjing University.  He is also a winner of National Outstanding Youth Fund in 1998, Distinguished   

Professor of the Cheung Kong scholars program in 1999. With his leadership applying multidisciplinary advanced technologies,   

the project team found that a series of active ingredients that led to an antidepressant candidate that is currently under a Phase II   

clinical study.  Because of his innovative research work, the project "Significant Research Achievements on the Ingredients of   

Medicinal Plants” won the second prize of National Natural Science Award in 2009.   

 Dr Chengyu ZHANG  

 Dr. ZHANG is a Professor and the Dean of the School of Life Science, Nanjing University, national outstanding youth fund gainer (2003), Distinguished Professor of Cheung Kong Scholars Program in 2004, National Pacesetter Plan in 2009, Jiangsu Province Ten Outstanding Youth in 2006, Tan Jiazheng Life Science Innovation Award winner in 2008, as a chief scientist for National "973" and"863" Projects.His research is focused in the field of molecular mechanism of Cell energy metabolism and its related disease pathogenesis. He has a total of 60 publications on the prestige journals including Cell, Nature and Science.

Dr. Yao YAO  

Dr. YAO is currently the Vice President of Quality Assurance and Regulatory Affairs of HLK. She also is the Associate Director of   

Pharmaceutical Technology Institute, Shenzhen Research Institute of NanjingUniversity. Prior to current positions, YAO was the   

manager of Regulatory Affairs and Clinical Quality Assurance at Teva Pharmaceuticals. Her responsibilities included, but not limited   

to, designing and managing regulatory strategies for drug development, reviewing and submitting marketing applications (IND, NDA,   

BLA, and ANDA), and providing compliance guidance and conduct quality audits.   

(5) General Administrative Office  

Office Manager:  Ms. Xuelan LIN  

 

5. Contact Information  

Address:  No. 6 Yuexing 3rd road, Southern District of Shenzhen High-tech Industrial Park, Nanshan District, Shenzhen, P.R. China.  

Phone: +86 755-86007001  

Email: info@hlkpharma.com, lin040201@njusz.com  



上一篇: 没有了
下一篇: 没有了